This database contains 97 studies, archived under the term: "Germany"
Click here to filter this large number of results.
Screening for dementia using telephone interviews. An evaluation and reliability study of the Telephone Interview for Cognitive Status (TICS) in its modified German version
Matrisch, M.,
Trampisch, U.,
Klaaßen-Mielke, R.,
Pientka, L.,
Trampisch, H.J.,
Thiem, U.
Background: To assess cognitive impairment or dementia in epidemiologic studies using telephone interviews for data acquisition, valid, reliable and short instruments suitable for telephone administration are required. For the Telephone Interview for Cognitive Status (TICS) in its modified German version, the only instrument used in Germany so far, more data on reliability and practicability are […]
Maintenance of health and relief for caregivers of elderly with dementia by using “initial case management”: experiences from the Lighthouse Project on Dementia, Ulm, ULTDEM-study
Lukas, A.,
Kilian, R.,
Hay, B.,
Muche, R.,
von Arnim, C.A.F.,
Otto, M.,
Riepe, M.,
Jamour, M.,
Denkinger, M.D.,
Nikolaus, T.
Background: When facing the well-known demographic development with an increasing number of people suffering from dementia, there is a need of programmes to support nursing relatives and care at home. Many support services have been established in the past few years but they are rarely used by the relatives and the patients. The purpose of […]
A phase II trial of tideglusib in Alzheimer’s disease
Lovestone, Simon,
Boadab, Mercè,
Dubois, Bruno,
Hüll, Michael,
Rinne, Juha O.,
Huppertz, Hans-Jürgen,
Calero, Miguel,
Andrés, María V.,
Gómez-Carrillo, Belén,
Leon, Teresa,
del Seri, Teodoro
Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer’s disease (AD). Objective: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. Methods: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14–26) AD patients on cholinesterase inhibitor and/or memantine treatment […]
Does an interdisciplinary network improve dementia care? Results from the IDemUck-study
Kohler, Leonore,
Meinke-Franze, Claudia,
Hein, Jurgen,
Fendrich, Konstanze,
Heymann, Romy,
Thyrian, Jochen,
Hoffmann, Wolfgang
Background: Most persons with dementia live at home and are treated in the primary care. However, the ambulatory health care system in Germany contains a lot of “interface problems” and is not optimized for the future challenges. Innovative concepts like regional networks in dementia care exist on a project level and need to be tested […]
Prediction of dementia in primary care patients
Jessen, Frank,
Wiese, Birgitt,
Bickel, Horst,
Eiffländer-Gorfer, Sandra,
Fuchs, Angela,
Kaduszkiewicz, Hanna,
Köhler, Mirjam,
Luck, Tobias,
Mösch, Edelgard,
Pentzek, Michael,
Riedel-Heller, Steffi G.,
Wagner, Michael,
Weyerer, Siegfried,
Maier, Wolfgang,
van den Bussche, Hendrik
Background: Current approaches for AD prediction are based on biomarkers, which are however of restricted availability in primary care. AD prediction tools for primary care are therefore needed. We present a prediction score based on information that can be obtained in the primary care setting.; Methodology/principal Findings: We performed a longitudinal cohort study in 3.055 […]
Memantine effects measured with the Relevant Outcome Scale for Alzheimer’s disease in an open-label, single-arm, multicenter clinical study
Holthoff, Vjera,
Ferris, Steven,
Gauthier, Serge,
Ihl, Ralf,
Robert, Philippe,
Winblad, Bengt,
Sternberg, Kati,
Tennigkeit, Frank
Objective: The Relevant Outcome Scale for Alzheimer’s disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer’s disease (AD) symptoms across all severity stages. The ROSA and four standard instruments — the Alzheimer’s disease Assessment Scale-cognitive (ADAS-cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) […]
Plasma proteomics for the identification of Alzheimer disease
Less-invasive biomarkers for early Alzheimer disease (AD) are urgently needed. The present study aimed to establish a panel of plasma proteins that accurately distinguishes early AD from physiological aging and to compare the findings with previous reports. Fifty-eight healthy controls (CON) and 109 patients with AD dementia were randomly split into a training (40%) and […]